Read by QxMD icon Read

Ovarian cancer biomarker

Nejc Kozar, Kristi Kruusmaa, Marko Bitenc, Rosa Argamasilla, Antonio Adsuar, Nandu Goswami, Darja Arko, Iztok Takač
The data presented here are related to the research paper entitled "Metabolomic profiling suggests long chain ceramides and sphingomyelins as a possible diagnostic biomarker of epithelial ovarian cancer." (Kozar et al., 2018) [1]. Metabolomic profiling was performed on 15 patients with ovarian cancer, 21 healthy controls and 21 patients with benign gynecological conditions. HPLC-TQ/MS was performed on all samples. PLS-DA was used for the first line classification of epithelial ovarian cancer and healthy control group based on metabolomic profiles...
June 2018: Data in Brief
Junxiu Liu, Dawei Liu, Jasmine J Liu, Chang Zhao, Shuzhong Yao, Liang Hong
Activity of the voltage-gated Nav1.5 sodium channel has been reported to be involved in cell proliferation, cancer invasion and gene expression. In addition, eicosapentaenoic acid (EPA) has recently been suggested to inhibit ovarian cancer cell growth and suppress tumor metastasis. The present study aimed to explore the association between EPA, the Nav1.5 sodium channel and ovarian cancer cells. Using patch-clamp technique and RNA interference approaches, sodium currents were recorded in epithelial ovarian cancer cells, and it was confirmed that the Nav1...
June 12, 2018: International Journal of Oncology
A Fu, H R Chang, Z F Zhang
Increasingly affordable high-throughput molecular profiling technologies have made feasible the measurement of omics-wide interindividual variations for the purposes of predicting cancer prognosis. While multiple types of genetic, epigenetic, and expression changes have been implicated in ovarian cancer, existing prognostic biomarker strategies are constrained to analyzing single classes of molecular variations. The extra predictive power afforded by the integration of multiple omics types remains largely unexplored...
April 20, 2018: Carcinogenesis
Pelin Muhsir, Emrah Çakmakçi, Serap Demir, Ayşe Ogan
The modification of magnetic nanoparticles (MNPs) via different routes for biomolecule binding is an attractive area of research. Waterborne thiol-ene suspension photopolymerization (TESP) can be a useful method for preparing functional MNPs. In this study, for the very first time waterborne TESP was performed in the presence of MNPs. Neat MNPs were coated and in situ functionalized with amine groups by using thiol-ene chemistry. Engrailed-2 (EN2) protein, a potential biomarker for various cancers such as prostate cancer, bladder cancer, breast cancer and ovarian cancer, is known to be a strong binder to a specific DNA sequence (50-TAATTA-30) to regulate transcription...
May 28, 2018: Colloids and Surfaces. B, Biointerfaces
Maggie K S Tang, Patrick Y K Yue, Philip P Ip, Rui-Lan Huang, Hung-Cheng Lai, Annie N Y Cheung, Ka Yu Tse, Hextan Y S Ngan, Alice S T Wong
The limitations of current anti-angiogenic therapies necessitate other targets with complimentary mechanisms. Here, we show for the first time that soluble E-cadherin (sE-cad) (an 80-kDa soluble form), which is highly expressed in the malignant ascites of ovarian cancer patients, is a potent inducer of angiogenesis. In addition to ectodomain shedding, we provide further evidence that sE-cad is abundantly released in the form of exosomes. Mechanistically, sE-cad-positive exosomes heterodimerize with VE-cadherin on endothelial cells and transduce a novel sequential activation of β-catenin and NFκB signaling...
June 11, 2018: Nature Communications
Emi Sato, Kentaro Nakayama, Sultana Razia, Kohei Nakamura, Masako Ishikawa, Toshiko Minamoto, Tomoka Ishibashi, Hitomi Yamashita, Kouji Iida, Satoru Kyo
AT-rich interactive domain 1A (ARID1A) and AT-rich interactive domain 1B (ARID1B) are subunits of the SWI/SNF chromatin complex. ARID1A is a tumor suppressor gene that is frequently mutated (46%) in ovarian clear cell carcinomas (OCCC). Loss of ARID1B in an ARID1A-deficient background eliminates the intact SWI/SNF complex, indicating that ARID1B is essential for the formation or stabilization of an intact SWI/SNF complex and, thus, the survival of ARID1A-mutant cancer cell lines. In this study, we investigated the clinicopathologic and prognostic relevance of ARID1B in OCCC by immunohistochemical analysis of 53 OCCC patient samples and loss-of-function experiments in OCCC cell lines...
June 8, 2018: International Journal of Molecular Sciences
Lorena Losi, Sergio Fonda, Sara Saponaro, Sonia T Chelbi, Cesare Lancellotti, Gaia Gozzi, Loredana Alberti, Luca Fabbiani, Laura Botticelli, Jean Benhattar
Aberrant methylation of multiple promoter CpG islands could be related to the biology of ovarian tumors and its determination could help to improve treatment strategies. DNA methylation profiling was performed using the Methylation Ligation-dependent Macroarray (MLM), an array-based analysis. Promoter regions of 41 genes were analyzed in 102 ovarian tumors and 17 normal ovarian samples. An average of 29% of hypermethylated promoter genes was observed in normal ovarian tissues. This percentage increased slightly in serous, endometrioid, and mucinous carcinomas (32%, 34%, and 45%, respectively), but decreased in germ cell tumors (20%)...
May 24, 2018: International Journal of Molecular Sciences
Maria Paraskevaidi, Camilo L M Morais, Kássio M G Lima, Katherine M Ashton, Helen F Stringfellow, Pierre L Martin-Hirsch, Francis L Martin
The current lack of an accurate, cost-effective and non-invasive test that would allow for screening and diagnosis of gynaecological carcinomas, such as endometrial and ovarian cancer, signals the necessity for alternative approaches. The potential of spectroscopic techniques in disease investigation and diagnosis has been previously demonstrated. Here, we used attenuated total reflection Fourier-transform infrared (ATR-FTIR) spectroscopy to analyse urine samples from women with endometrial (n = 10) and ovarian cancer (n = 10), as well as from healthy individuals (n = 10)...
June 7, 2018: Analyst
Leda Severi, Lorena Losi, Sergio Fonda, Laura Taddia, Gaia Gozzi, Gaetano Marverti, Fulvio Magni, Clizia Chinello, Martina Stella, Jalid Sheouli, Elena I Braicu, Filippo Genovese, Angela Lauriola, Chiara Marraccini, Alessandra Gualandi, Domenico D'Arca, Stefania Ferrari, Maria P Costi
Proteomics and bioinformatics are a useful combined technology for the characterization of protein expression level and modulation associated with the response to a drug and with its mechanism of action. The folate pathway represents an important target in the anticancer drugs therapy. In the present study, a discovery proteomics approach was applied to tissue samples collected from ovarian cancer patients who relapsed after the first-line carboplatin-based chemotherapy and were treated with pemetrexed (PMX), a known folate pathway targeting drug...
2018: Frontiers in Pharmacology
Kshipra M Gharpure, Olivia D Lara, Yunfei Wen, Sunila Pradeep, Chris LaFargue, Cristina Ivan, Rajesha Rupaimoole, Wei Hu, Lingegowda S Mangala, Sherry Y Wu, Archana S Nagaraja, Keith Baggerly, Anil K Sood
Primary debulking surgery followed by adjuvant chemotherapy is the standard treatment for ovarian cancer. Residual disease after primary surgery is associated with poor patient outcome. Previously, we discovered ADH1B to be a molecular biomarker of residual disease. In the current study, we investigated the functional role of ADH1B in promoting ovarian cancer cell invasiveness and contributing to residual disease. We discovered that ADH1B overexpression leads to a more infiltrative cancer cell phenotype, promotes metastasis, increases the adhesion of cancer cells to mesothelial cells, and increases extracellular matrix degradation...
May 18, 2018: Oncotarget
Mariana Rezende Alves, Natalia Cruz E Melo, Mateus Camargo Barros-Filho, Nayra Soares do Amaral, Felipe Ilelis de Barros Silva, Glauco Baiocchi Neto, Fernando Augusto Soares, Louise de Brot Andrade, Rafael Malagoli Rocha
Anterior gradient 2 protein belongs to a family of chaperone-like proteins, namely protein disulfide isomerase. Generally, AGR2 is highly expressed in mucus-secreting cells and endocrine organs, and in this study, we aimed to evaluate AGR2 and cell cycle molecules in epithelial ovarian cancer and its implications on prognosis. One hundred seventy-five patient's samples that were diagnosed with primary epithelial ovarian carcinoma were selected. All the patients were treated with platinum-taxane standard chemotherapy after surgery and CA125 serum levels were routinely determined...
May 29, 2018: Cancer Medicine
Jiayu Shen, Xiaoqing Zhu, Jing Fei, Pengyao Shi, Shuqian Yu, Jianwei Zhou
Ovarian cancer is the leading cause of female gynecological cancer mortality. Most patients with ovarian cancer are diagnosed with advanced stage because of lack of early symptoms, physical signs, and sensitive tumor biomarkers. The standard treatment includes cytoreductive surgery and platinum-based chemotherapy (usually platinum combined with paclitaxel). Despite that postoperative adjuvant chemotherapy prolongs survival time, most patients go through relapse within 6-12 months after the treatment. Thus, elucidating the molecular mechanism in cancer development is essential to promote early diagnosis and novel treatments...
2018: OncoTargets and Therapy
Rachel Grisham, Kathleen N Moore, Michael S Gordon, Wael Harb, Gwendolyn R Cody, Darragh F Halpenny, Vicky Makker, Carol Aghajanian
PURPOSE: Epithelial ovarian cancer (EOC) is a molecularly diverse disease. Mitogen-activated protein kinase kinase (MEK) inhibition targets tumors harboring mitogen-activated protein kinase (MAPK) pathway alterations and enhances paclitaxel-induced apoptosis in EOC. This phase Ib study evaluated the MEK inhibitor binimetinib combined with paclitaxel in patients with platinum-resistant EOC. EXPERIMENTAL DESIGN: Patients received intravenous (IV) weekly paclitaxel with oral binimetinib in three different administration schedules...
May 29, 2018: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
Kristina Lindemann, Bo Gao, Cristina Mapagu, Sian Fereday, Catherine Emmanuel, Kathryn Alsop, Nadia Traficante, Paul R Harnett, David D L Bowtell, Anna deFazio
OBJECTIVE: The aim of this study was to compare response rates and survival in women with "platinum resistant" epithelial ovarian cancer (EOC) who received further platinum-based or non‑platinum chemotherapy for treatment at first relapse. METHODS: Patients with high-grade EOC (including fallopian tube and peritoneal cancer) of all histologies recruited to the Australian Ovarian Cancer Study (AOCS) and treated with platinum-based primary chemotherapy were included...
May 25, 2018: Gynecologic Oncology
Yaqing Huang, Junyu Shi, Yun Xu
Ovarian cancer is a markedly heterogeneous malignancy characterized by various histological subtypes. Molecular biomarkers have been indicated to serve significant functions in the early diagnosis and treatment of early-stage ovarian cancer. However, the detailed mechanism underlying the tumorigenesis of ovarian cancer remains unclear. The present study aimed to identify a novel long non-coding RNA in patients with ovarian cancer. Nicotinamide nucleotide transhydrogenase-antisense 1 (NNT-AS1) was markedly downregulated in patients with ovarian cancer and in cultured human ovarian cancer cells...
June 2018: Oncology Letters
Qing Li, Juan Zhang, Juan Zhou, Binglie Yang, Pingping Liu, Lei Cao, Lei Jing, Hua Liu
Cisplatin-resistant ovarian cancer occurs in patients with ovarian cancer treated with cisplatin-based chemotherapy, which results in tumor progression during treatment, or recurrence of the tumor within 6 months of the treatment. It is vital that a novel biomarker for diagnosis, or an efficient therapeutic target of cisplatin-resistant ovarian is identified. Long non-coding (lnc)RNAs were determined to serve critical functions in a variety of distinct types of cancer, including ovarian cancer; however, there is limited knowledge regarding the differential expression levels of lncRNAs in cisplatin-resistant and cisplatin-sensitive ovarian cancer...
June 2018: Oncology Letters
Hanxiao Tang, Yongsheng Zhang
It is hypothesized that there may be common characteristics between the genetic regulatory networks of different diseases. To identify these potential similarities, analysis of overlapping differentially expressed genes (DEGs) in several diseases, which are believed to be associated in traditional Chinese medicine (TCM) was performed in the present study. The gene expression profiles associated with depression, papillary thyroid carcinoma (PTC) and uterine fibroids (UF) were preliminarily analyzed using Gene Expression Omnibus 2R tools...
June 2018: Experimental and Therapeutic Medicine
Zhen-Hua Du, Fang-Fang Bi, Lei Wang, Qing Yang
BACKGROUND: By using a high-throughput sequencing technique, we sought to delineate genetic alterations in recurrent ovarian cancer patients and further compare genetic changes in drug-resistant and -sensitive recurrent ovarian cancer patients. We also sought to study the specificity, sensitivity, and consistency of DNA biomarkers in liquid biopsy specimens and ovarian cancer tissue DNA. METHODS: Tumor tissue specimens and blood samples were obtained from pathologically proven recurrent ovarian cancer patients...
May 24, 2018: Molecular Genetics & Genomic Medicine
Darja Kanduc
Anti-ovarian cancer vaccines based on minimal immune determinants uniquely expressed in ovarian cancer biomarkers and absent in the human proteome appear to promise a high level of sensitivity and specificity for early ovarian cancer immunodiagnostics, immunoprevention, and immunotherapy. In this context, the present study analyses three ovarian cancer biomarkers - namely sperm surface protein Sp17, WAP four-disulfide core domain protein 2, and müllerian-inhibiting substance - and describes a methodology for constructing ovarian cancer biomarker-derived oligopeptide constructs that might be useful for developing new diagnostic and immunotherapeutic approaches...
May 24, 2018: Current Drug Discovery Technologies
Panagiotis G Adamopoulos, Georgios D Raptis, Christos K Kontos, Andreas Scorilas
The human SR-related CTD associated factor 1 (SCAF1) gene is a new member of the human SR (Ser/Arg-rich) superfamily of pre-mRNA splicing factors, which has been discovered and cloned by members of our lab. SCAF1 interacts with the CTD domain of the RNA polymerase II polypeptide A and is firmly involved in pre-mRNA splicing. Although it was found to be expressed widely in multiple human tissues, its mRNA levels vary a lot. The significant relation of SCAF1 with cancer has been confirmed by many studies, since SCAF1 mRNA transcript was found to be overexpressed in breast and ovarian tumors, confirming its significant prognostic value as a cancer biomarker in both these human malignancies...
May 19, 2018: Gene
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"